18th week of 2010 patent applcation highlights part 45 |
Patent application number | Title | Published |
20100111817 | TITANIUM OXIDE PHOTOCATALYST AND METHOD FOR PRODUCING THE SAME - A titanium oxide photocatalyst that is capable of improving a decomposition rate, and a method for producing the same are provided. The titanium oxide photocatalyst of the present invention is a titanium oxide photocatalyst containing at least an anatase-type titanium oxide and fluorine, wherein a content of the fluorine is 2.5 wt % to 3.5 wt %, and 90 wt % or more of the fluorine is chemically bonded to the anatase-type titanium oxide. | 2010-05-06 |
20100111818 | REMOVAL OF CONTAMINANTS FROM BY-PRODUCT HYDROCHLORIC ACID - The present disclosure is drawn to a method for removing colloidal titanium dioxide and titanium oxychloride from by-product hydrochloric acid, typically without the use of metallic hydroxides and/or other neutralizing agents. Often, the decontaminated hydrochloric acid product is commercial grade and has concentrations greater than 85 wt % of the concentration of untreated by-product hydrochloric acid. The method includes adding phosphate ion source and quaternary amine or other precipitating agent to the by-product hydrochloric acid to cause the titanium dioxide and the titanium oxychloride to form a precipitate. In one embodiment, the method further includes heating at least one of the phosphate ion source, the quaternary amine or alternative precipitating agent, the by-product hydrochloric acid, or combination thereof. The precipitate can then be separated from the acid, thus producing a decontaminated hydrochloric acid product with reduced levels of titanium and other contaminants. | 2010-05-06 |
20100111819 | CHEMICAL PROCESS TO PRODUCE HYDROGEN CHLORIDE AND CHLORIDE-FREE COMPOUND POTASSIUM SULFATE FERTILIZERS OR OTHER METAL SULFATES - A method is disclosed for production of a sulfate-containing salt and anhydrous gaseous HCl from a metal chloride (MCl | 2010-05-06 |
20100111820 | METHOD OF DETERMINING LASER STABILITIES OF OPTICAL MATERIAL, CRYSTALS OBTAINED WITH SAID METHOD, AND USES OF SAID CRYSTALS - A method of selecting suitable laser-stable optical material for making an optical element, especially for transmission at wavelengths under 200 nm, is described. It includes a first pre-irradiation to produce radiation damage, subsequent excitation of induced fluorescence with light at between 350 to 700 nm at least ten minutes after the first pre-irradiation and measurement of induced fluorescence intensities at one or more wavelengths between 550 nm and 810 nm. After the fluorescence intensity measurement a second pre-irradiation is performed with an at least 1000-fold higher energy than in the first pre-irradiation and then induced fluorescence intensities are again measured to determine the increase in the fluorescence intensities. The materials determined to have suitable laser stability are used for making lenses, prisms, light-conducting rods, optical windows and optical devices for DUV lithography, especially steppers and excimer lasers, integrated circuits, computer chips as well as other electronic devices. | 2010-05-06 |
20100111821 | GYPSUM STABILISATION METHOD - The invention relates to a method for reducing or eliminating the soluble content of pollutants in gypsum or in compounds containing gypsum, wherein the gypsum or gypsum-containing compound is mixed with additives that contain or can generate aluminium oxide. More specifically, the gypsum originates from gas desulphurisation and the pollutant is fluorine. | 2010-05-06 |
20100111822 | Method for fabricating a high specific surface area mesoporous alumina - A method for fabricating a high specific surface area mesoporous alumina is disclosed, which includes the following steps: (a) providing a water solution containing an aluminum salt and a fluoro-surfactant; (b) adding concentrated hydrochloric acid to adjust the PH value of the solution to about 6.0 to 8.0; (c) aging the solution at 70° C. to 110° C. for 12 to 20 hours; (d) washing the precipitate with water; (e) washing the precipitate with an organic solvent; (f) drying the precipitate; and (g) sintering the precipitate in a furnace of 500° C. to 1000° C. | 2010-05-06 |
20100111823 | METHODS AND SYSTEMS FOR PRODUCING HYDROGEN AND SYSTEM FOR PRODUCING POWER - Provided herein are methods and systems of producing hydrogen using ammonia borane, which has a high hydrogen density while being stable and easily stored. Ammonia borane may be exothermically reacted with a strong oxidizer, such as a mixture of hydrogen peroxide and water. The reaction between ammonia borane and the strong oxidizer may occur spontaneously and may produce heat. Unreacted ammonia borane may be exposed to and thermally decomposed using the heat produced during the exothermic reaction between ammonia borane and the strong oxidizer. The heat may be retained by performing the reactions in a vessel or reactor including a material capable of retaining the heat. A high gravimetric hydrogen yield is obtained from the reaction of ammonia borane with hydrogen peroxide and the thermal decomposition of unreacted ammonia borane. Hydrogen production using the methods and systems may yield a high gravimetric hydrogen content of at least about 10%. | 2010-05-06 |
20100111824 | HYDROGEN PRODUCTION METHOD - In a process for producing hydrocarbonaceous educts, the starting material is autothermally gasified by non-catalytic partial oxidation by adding oxygen-containing gas and hydrogen at temperatures of 1200 to 1500° C. and pressures of 15 to 100 bar | 2010-05-06 |
20100111825 | REDOX ACTIVE MASS FOR A CHEMICAL LOOPING COMBUSTION PROCESS - A redox mass for chemical looping combustion processes includes a redox pair or set of pairs having a material able to be alternatively oxidized and reduced between CuO and Cu, between Cu | 2010-05-06 |
20100111826 | Set-Up for Production of Hydrogen Gas By Thermo-Chemical Decomposition of Water Using Steel Plant Slag and Waste Materials - A novel method for producing hydrogen gas from water comprising adding water to the slag and carbonaceous flux to produce hydrogen by thermo-chemical decomposition of water. | 2010-05-06 |
20100111827 | PRODUCTION PROCESS FOR NOx ADSORPTION MATERIAL AND NOx ADSORPTION MATERIAL - A zeolite is impregnated with a ferric chloride aqueous solution; and thereafter it is heated at 500° C.-700° C. in an atmosphere that is free from moisture, thereby subjecting Fe to ion exchange. By means of heating it in an atmosphere that is free from moisture, it is possible to produce an NO | 2010-05-06 |
20100111828 | MICROPOROUS CRYSTALLINE SILICOALUMINO/(METALLO) ALUMINOPHOSPHATE MOLECULAR SIEVE AND METHOD OF SYNTHESIS THEREOF - A novel microporous crystalline silicoalumino/(metallo)aluminophosphate molecular sieve framework (designated as BPC-1), having in its as-synthesized form, an X-ray diffraction pattern including the lines listed in Table 1, and method of its synthesis using 4-dimethylaminopyridine as organic templating agent in fluoride medium under microwave-hydrothermal conditions. | 2010-05-06 |
20100111829 | FLOWABLE COMPOSITION THAT HARDENS ON DELIVERY TO A TARGET TISSUE SITE BENEATH THE SKIN - Flowable compositions and methods are provided for delivering a therapeutic agent at or near a target tissue site beneath the skin of a patient, the flowable composition comprising (i) a solvent and (ii) an effective amount of the therapeutic agent, the flowable composition being capable of hardening to form a drug depot at a physiological temperature or as solvent contacts bodily fluid at or near the target tissue site, wherein the drug depot is capable of releasing the therapeutic agent over a period of at least one day and the target tissue site comprises at least one muscle, ligament, tendon, cartilage, spinal disc, spinal foraminal space near the spinal nerve root, facet or synovial joint, or spinal canal. In some embodiments, an implantable drug depot for delivering a therapeutic agent is provided, the implantable drug depot comprising (i) a chamber; and (ii) a flowable composition comprising an effective amount of a therapeutic agent disposed within the chamber of the drug depot, the flowable composition capable of hardening when the drug depot is delivered at or near the target tissue site. | 2010-05-06 |
20100111830 | Compositions and methods for surface abrasion with frozen particles - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 2010-05-06 |
20100111831 | Compositions and methods for surface abrasion with frozen particles - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 2010-05-06 |
20100111832 | Compositions and methods for surface abrasion with frozen particles - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 2010-05-06 |
20100111833 | Compositions and methods for surface abrasion with frozen particles - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 2010-05-06 |
20100111834 | Compositions and methods for therapeutic delivery with frozen particles - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 2010-05-06 |
20100111835 | Compositions and methods for therapeutic delivery with frozen particles - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 2010-05-06 |
20100111836 | Compositions and methods for therapeutic delivery with frozen particles - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 2010-05-06 |
20100111837 | Compositions and methods for biological remodeling with frozen particle compositions - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 2010-05-06 |
20100111838 | BRAIN-LOCALIZING POLYPEPTIDES COMPRISING A MULTIVALENT BINDING MOIETY AND IMPROVED METABOLIC STABILITY - Brain-localizing polypeptides carrying a reactive group for linking to a molecule that does not have brain-localizing activity were successfully produced by introducing at least two lysine residues into cyclized polypeptides having a brain-localizing motif sequence. These polypeptides have improved metabolic stability compared to conventional brain-localizing polypeptides, and can efficiently translocate desired molecules into the brain. | 2010-05-06 |
20100111839 | SELECTIVE INHIBITORS OF TRANSLESION DNA REPLICATION - An agent for inhibiting P-glycoproteins comprises a non-natural adenine ribose analog. | 2010-05-06 |
20100111840 | STABILIZED THERAPEUTIC AND IMAGING AGENTS - Stabilized lipid construct comprising a liposome or polymerized vesicle, a targeting entity, a therapeutic entity, and a stabilizing entity are provided, as well as methods for their preparation and use. | 2010-05-06 |
20100111841 | Compositions and methods for surface abrasion with frozen particles - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 2010-05-06 |
20100111842 | Compositions and methods for therapeutic delivery with frozen particles - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 2010-05-06 |
20100111843 | Compositions and methods for therapeutic delivery with frozen particles - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 2010-05-06 |
20100111844 | Compositions and methods for therapeutic delivery with frozen particles - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 2010-05-06 |
20100111845 | Compositions and methods for therapeutic delivery with frozen particles - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 2010-05-06 |
20100111846 | Compositions and methods for delivery of frozen particle adhesives - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 2010-05-06 |
20100111847 | Compositions and methods for administering compartmentalized frozen particles - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 2010-05-06 |
20100111848 | Compositions and methods for administering compartmentalized frozen particles - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 2010-05-06 |
20100111849 | Compositions and methods for administering compartmentalized frozen particles - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 2010-05-06 |
20100111850 | Compositions and methods for administering compartmentalized frozen particles - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 2010-05-06 |
20100111851 | DIAGNOSIS AND TREATMENT OF CANCER BY USING ANTI-PRG-3 ANTIBODY - The present invention discloses an antibody capable of binding to the PRG-3 protein and inhibiting the growth of cells expressing the PRG-3 protein. The growth inhibitory activity is cytotoxic activity, such as antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity. The present invention also discloses a pharmaceutical composition, cell growth inhibitor, and an anticancer agent comprising the antibody of the present invention as an active ingredient. Examples of the type of cancer include hepatocellular carcinoma, lung cancer, colon cancer, and glioblastoma. In addition, the present invention discloses a method for diagnosing cancer by detecting expression of the PRG-3 protein or the gene encoding the PRG-3 protein, as well as a diagnostic agent and kit for use in the method. | 2010-05-06 |
20100111852 | Anti-Claudin 3 Monoclonal Antibody and Treatment and Diagnosis of Cancer Using the Same - Monoclonal antibodies that bind specifically to Claudin 3 expressed on cell surface are provided. The antibodies of the present invention are useful for diagnosis of cancers that have enhanced expression of Claudin 3, such as ovarian cancer, prostate cancer, breast cancer, uterine cancer, liver cancer, lung cancer, pancreatic cancer, stomach cancer, bladder cancer, and colon cancer. The present invention provides monoclonal antibodies showing cytotoxic effects against cells of these cancers. Methods for inducing cell injury in Claudin 3-expressing cells and methods for suppressing proliferation of Claudin 3-expressing cells by contacting Claudin 3-expressing cells with a Claudin 3-binding antibody are disclosed. The present application also discloses methods for diagnosis or treatment of cancers. | 2010-05-06 |
20100111853 | ANTIBODIES THAT BIND TO IL-12 AND METHODS OF PURIFYING THE SAME - Anti-IL-12 antibodies are disclosed herein, including antigen-binding portions thereof. One or more methods for isolating and purifying anti-IL-12 antibodies from a sample matrix is presented. These isolated anti-IL-12 antibodies can be used in a clinical setting as well as in research and development. Pharmaceutical compositions comprising isolated anti-IL-12 antibodies are also described. | 2010-05-06 |
20100111854 | Frozen compositions and methods for piercing a substrate - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 2010-05-06 |
20100111855 | Frozen compositions and methods for piercing a substrate - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 2010-05-06 |
20100111856 | ZIRCONIUM-RADIOLABELED, CYSTEINE ENGINEERED ANTIBODY CONJUGATES - Antibodies are engineered by replacing one or more amino acids of a parent antibody with non cross-linked, highly reactive cysteine amino acids. Antibody fragments may also be engineered with one or more cysteine amino acids to form cysteine engineered antibody fragments (ThioFab). Methods of design, preparation, screening, and selection of the cysteine engineered antibodies are provided. Cysteine engineered antibodies (Ab) are conjugated with one or more zirconium complex (Z) labels through a linker (L) to form cysteine engineered zirconium-labeled antibody conjugates having Formula I: | 2010-05-06 |
20100111857 | Compositions and methods for surface abrasion with frozen particles - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 2010-05-06 |
20100111858 | Diangostic and Therapeutic Cyclooxygenase-2 Binding Ligands - The present invention provides conjugates useful for the diagnosis and treatment of diseases associated with the over-expression of COX-2. The conjugates comprise a selective COX-2 targeting carrier, a metal coordinating moiety, and a linker chemically linking the metal coordinating moiety to the carrier. The metals coordinated by the metal coordinating moiety are selected from paramagnetic or radioisotopes. The invention also includes kits comprising a conjugate and a radioisotope solution. | 2010-05-06 |
20100111859 | Visualization of Biological Material by the Use of Coated Contrast Agents - A method for visualizing biological material, preferably by MRI, comprising the steps of: (i) bringing a population of coated nanoparticles into contact with said biological material, each of which nanoparticles comprises a) a metal oxide of a transition metal, said metal oxide preferably being paramagnetic and preferably comprising a lanthanide (+III) such as gadolinium (+III), and b) a coating covering the surface of the core particle, and (ii) recording the image; wherein the coating is hydrophilic and comprises a silane layer which is located next to the surface of the core particle and comprises one or more different silane groups which each comprises an organic group R and a silane-siloxane linkage where a) R comprises a hydrophilic organic group R′ and a hydrophobic spacer B, b) O is oxygen directly binding to a surface metal ion of the metal oxide, and c) C is carbon and is also part of B. A composition for visualization and methods for the manufacture of the nanoparticles and core particles are also disclosed. Visualization includes imaging by MR, CT, X-ray, near IR fluorescence, PET, microscopying etc with the largest advantages accomplished for in-vivo imaging. | 2010-05-06 |
20100111860 | Radioactive material containing chitosan for inhibiting cancer and preparation method thereof - A radioactive material containing chitosan for inhibiting cancer and a preparation method thereof are revealed. The adioactive material containing chitosan is formed by using SOCTA chelating agent to connect chitosan and radionuclides such as | 2010-05-06 |
20100111861 | DETECTION AND QUANTIFICATION OF ABASIC SITE FORMATION IN VIVO - A method of measuring the efficacy of an anticancer agent in generating abasic (AP) sites in DNA of cancer cells of a subject includes administering to the subject an anticancer agent that generates AP sites in at least one cancer cell and an AP endonuclease inhibitor probe. The AP endonuclease inhibitor probe includes a detection moiety for detecting the probe in the subject. The amount of probe bound to cancer cells of the subject is then measured. The amount of probe bound to cancer cells of the subject is indicative of efficacy of the anticancer agent in generating AP sites in cancer cells of the subject. | 2010-05-06 |
20100111862 | RADIOLABELLED INHIBITORS OF THE GLYCINE 1 TRANSPORTER - The present invention relates to novel radiolabelled inhibitors of formula I for the Glycine 1 transporter (GlyT1), useful for the labelling and diagnostic imaging of the glycine 1 transporter functionality. | 2010-05-06 |
20100111863 | 18F-LABELLED FOLATES - The present invention is directed towards new | 2010-05-06 |
20100111864 | 18F-LABELLED FOLATES - The present invention is directed towards a new method of synthesis of | 2010-05-06 |
20100111865 | CONTRAST AGENTS - The present invention provides novel compounds and pharmaceutical compositions containing such compounds, wherein the compounds have affinity for proteoglycans. The compounds comprise an amino acid based core unit linked to positively charged moieties. The compounds further comprise at least one imaging moiety detectable in in vivo imaging making the compounds useful as diagnostic contrast agents for imaging of proteoglycans, such as heparan sulphate proteoglycans. | 2010-05-06 |
20100111866 | Receptor and Antigen Targeted Prodrug - The present invention relates to a prodrug which comprises at least one pharmaceutically and/or diagnostically active compound bound by a cleavable linker, a receptor and/or antigen targeting moiety and a protein-binding moiety which is capable of binding to a carrier molecule. | 2010-05-06 |
20100111867 | CARBORANE-PHOSPHONIUM COMPOUNDS AND THEIR USE IN BORON NEUTRON CAPTURE THERAPY AND IMAGING - The invention describes compounds for use in BCNT. These compounds comprise a carborane group coupled to a phosphorus containing group. The compounds may comprise a carborane group coupled to a phosphonium group. | 2010-05-06 |
20100111868 | MONOCLONAL ANTIBODIES FOR NEUTRALIZING ANTHRAX TOXIN - Isolated monoclonal antibodies that bind and/or neutralize anthrax protective antigen (PA) are disclosed as well as hybridomas secreting such antibodies. The invention also provides anti-PA fragments of the antibodies of the invention and recombinantly produced antibodies. Also provided are pharmaceutical compositions containing the antibodies or antibody fragments and uses and methods involving same. | 2010-05-06 |
20100111869 | Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosmetic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue - A stinging cell comprising an exogenous polynucleotide capable of expressing a therapeutic, cosmetic or diagnostic agent in the stinging cell is provided. | 2010-05-06 |
20100111870 | EVALUATION METHOD AND SCREENING METHOD FOR SUBSTANCE HAVING ACTION OF ACTIVATING/SUPPRESSING INNATE IMMUNITY, AGENT AND FOOD PRODUCT FOR ACTIVATING/SUPPRESSING INNATE IMMUNE MECHANISM AND METHOD FOR PRODUCING THE SAME - It is intended to provide an evaluation method and a screening method capable of eliminating a substance that disturbs in vivo kinetics in an individual and capable of simply and easily searching a substance having an action of activating/suppressing an innate immune mechanism without being affected by LPS derived from bacteria, which can be contaminated during the search, as well as a drug and a food for activating/suppressing the innate immune mechanism, and methods of producing the same. The present invention provides a method of evaluating or screening the substance having the action of activating/suppressing the innate immune mechanism using a muscular contraction of an organism having the innate immune mechanism as an indicator, and methods of producing the drug and the food for activating/suppressing the innate immune mechanism. Also, an innate immunity activator and the food having the action of activating the innate immune mechanism containing the substance having the action of contracting the muscle of the organism having the innate immune mechanism, and an innate immunity suppressor and the food having the action of suppressing the innate immunity containing the substance having the action of suppressing the contraction of the muscle of the organism having the innate immune mechanism are provided. | 2010-05-06 |
20100111871 | PHOTOACOUSTIC PROBES AND METHODS OF IMAGING - Embodiments of the present disclosure provide for photoacoustic probes, methods of determining the presence and location of a specific target, methods of determining the presence and location of an enzyme, methods of determining the presence and location of a specific target and an enzyme, and the like. | 2010-05-06 |
20100111872 | System and method for modulating and optimizing immunotherapy - A method for modulating a subject's type of immune response to a cancer treatment. The method comprises the steps of: (a) obtaining a sample from subject; (b) assessing the sample to detect IgG antibodies or IgG isotypes in the sample; (c) if IgG antibodies or IgG isotypes are detected, then identifying and quantifying their expression; (d) comparing the quantified IgG antibodies or IgG isotypes with a control to determine the changes, and characterize the immune response. The changes in expression of IgG antibodies or IgG isotypes are indicative of the type of immune response to the cancer treatment. Steps (a) through (f) are repeated for each of a series of spaced-apart time points. The series of characterized immune responses are assessed to determine the subject's responsiveness to the cancer treatment. The cancer treatments are then modulated to affect desired changes in expression of IgG antibodies or IgG isotypes. | 2010-05-06 |
20100111873 | TREATING CANCER WITH VIRAL NUCLEIC ACID - This document provides methods and materials related to the use of nucleic acid coding for viruses to reduce the number of viable cancer cells within a mammal. For example, methods for using infectious nucleic acid to treat cancer, engineered viral nucleic acid, methods for making engineered viral nucleic acid, methods for identifying infectious nucleic acid for treating cancer, methods and materials for controlling virus-mediated cell lysis, and methods and materials for assessing the control of virus-mediated cell lysis are provided. | 2010-05-06 |
20100111874 | METHOD OF CANCER DETECTION AND TREATMENT - The present invention provides methods for detecting and treating cancer. In some embodiments, levels of ISG15 are determined, and topoisomerase I and II inhibitors as well as other DNA-damaging agents plus agents that increase the expression of ISG15 are selected and administered. | 2010-05-06 |
20100111875 | TRISUBSTITUTED TRIAZAMACROCYCLIC COMPOUNDS AND THEIR USE AS CONTRAST AGENTS - The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds. More specifically the iodine containing compounds are chemical compounds containing a saturated triaza cyclic central moiety containing carbonyl functions allowing for the arrangement of three iodinated phenyl groups bound thereto. The invention also relates to the use of such diagnostic compositions as contrast agents in diagnostic imaging and in particular in X-ray imaging and to contrast media containing such compounds. | 2010-05-06 |
20100111876 | USE OF METAL NANOPARTICLES IN THE DIAGNOSIS OF ALZHEIMER'S DISEASE - The invention relates to the use of metal nanoparticles for the preparation of a composition for diagnosing Alzheimer's disease by MRI. | 2010-05-06 |
20100111877 | Foam disinfectant - The invention relates to an aqueous foam disinfectant comprised of a special surfactant system, which consists of non-ionic and amphoteric surfactants, and of a synergistic disinfectant constituent, which consists of an antimicrobial agent having amino groups and of at least one additional antimicrobial agent. | 2010-05-06 |
20100111878 | SKIN-CARE COMPOSITIONS AND USES THEREOF - Composition of a Dead Sea extract and at least one plant extract of a Himalayan origin are provided for topical applications. | 2010-05-06 |
20100111879 | SACCHARIDE FOAMABLE COMPOSITIONS - A foamable composition, containing a saccharide for use in the treatment of various disorders including: water, a saccharide, about 0.2% to about 5% by weight of a surface-active agent, about 0.01% to about 5% by weight of at least one polymeric agent selected from a bio-adhesive agent, a gelling agent, a film forming agent and a phase change agent, and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition. | 2010-05-06 |
20100111880 | NOVEL 1,3-OXATHIANE COMPOUNDS AND THEIR USE IN FLAVOR AND FRAGRANCE COMPOSITIONS - The present invention relates to novel 1,3-oxathiane compounds represented by Formula I: | 2010-05-06 |
20100111881 | Polymeric anti-microbial agents - Polymeric anti-microbial agents produced by substituting the nitrogen atoms in the backbone of ethylenimine polymers, for example, substitution with aralkyl groups, are provided. The agents are believed to have low human toxicity while being effective against a variety of pathogens and are useful in applications involving human contact, such as cosmetics, hair care products and textiles, as well as in applications with much less human contact, such as coatings. | 2010-05-06 |
20100111882 | PROCESS FOR MANUFACTURING A SWEETENER AND USE THEREOF - Highly purified Stevioside and Rebaudioside A were prepared from sweet glycoside extracts obtained from | 2010-05-06 |
20100111883 | CYCLODEXTRIN FORMULATIONS - The present invention is directed to various formulations comprising one or more cyclodextrins, said formulations being particularly useful to treating or preventing viral infections. In specific embodiments, the formulations comprise non-water based gels, throat and nose sprays, nose gels, lip balms, and emulsions. | 2010-05-06 |
20100111884 | UV ABSORBER FORMULATIONS - Disclosed is a UV filter composition comprising (a) an organic UV absorber of formula (1), wherein R | 2010-05-06 |
20100111885 | Hair-Shape Controlling Composition - The invention provides a hair shape-controlling composition which has excellent applicability to hair, which causes less damage to permanent-waved hair or straightened hair, which can provide treated hair with an excellent texture as expected, and which does not impede a glossy appearance of treated hair. The hair shape-controlling composition including a first component containing a reducing agent and an alkaline agent, and a second component containing an oxidizing agent is provided by containing a specific hydroxy-ether-amine compound or a specific quaternary ammonium salt. | 2010-05-06 |
20100111886 | HAIR STYLING COMPOSITION - Provided is a hair-styling composition, which preferably includes polyvinylpyrrolidone, at least one additional film former, at least one thickener and water, wherein the composition is substantially free of carbomer, and when applied to human hair, exhibits at least about 80% curl retention after about 2 hours under conditions of about 85% relative humidity and about 75° F. Also provided is a method of styling keratinous fibers with the composition of the present invention and a method of controlling the frizz condition of keratinous fibers with the composition. | 2010-05-06 |
20100111887 | COMPOSITION WITH A HEATING EFFECT CONTAINING FOAMING SURFACTANTS - Composition containing, in an anhydrous medium, at least one exothermic metal salt, at least a first foaming surfactant and at least a second foaming surfactant, the composition containing less than 1% of gelling agent. | 2010-05-06 |
20100111888 | Organic Compounds and Compositions Having the Ability to Modulate Fragrance Compositions - Disclosed are compounds having the ability to modulate, namely to improve, enhance and or modify fragrance compositions due to their ability to inhibit cytochrome P450 enzymes, e.g. CYP2A13 and CYP2B6. | 2010-05-06 |
20100111889 | Malodor Control System - A malodor control system suitable for use in disposable articles, such as disposable cleaning wipes, baby wipes, or skin care wipes, is disclosed. The system may comprise an aldehyde, an ester, an ionone, and optionally a macrocyclic musk. The system may optionally include a perfume. | 2010-05-06 |
20100111890 | USE IN PERFUMERY AND FLAVORING AND PROCESS FOR THE PREPARATION OF 5,5-DIMETHYL-3-ETHYL-3,4-DIHYDROFURAN-2-ONE - The invention relates to the use of 5,5-dimethyl-3-ethyl-3,4-dihydrofuran-2-one (A), named “Noxolide” by the applicant, as an olfactory agent in perfumery, and also as a food flavouring. The invention also relates to a novel process for the preparation of 5,5-dimethyl-3-ethyl-3,4-dihydrofuran-2-one. | 2010-05-06 |
20100111891 | LINEAR POLYOL STABILIZED POLYFLUOROACRYLATE COMPOSITIONS - The present invention is directed to compositions of a linear polyol and a salt of a crosslinked cation exchange polymer comprising a fluoro group and an acid group. These compositions are useful to bind potassium in the gastrointestinal tract. | 2010-05-06 |
20100111892 | CROSSLINKED POLYFLUOROACRYLIC ACID AND PROCESSES FOR THE PREPARATION THEREOF - The present invention is directed to crosslinked cation exchange polymers comprising a fluoro group and an acid group and being a polymerization product of at least three monomers. Pharmaceutical compositions of these polymers are useful to bind potassium in the gastrointestinal tract. | 2010-05-06 |
20100111893 | Silicone Elastomer Exfoliating Compositions - Compositions of the present invention comprise from about 40-99% of an aqueous suspension of silicone elastomer powder in a cosmetically acceptable vehicle. The compositions are useful as skin exfoliants when mechanical agitation is supplied, for example by rubbing with a hand. After exfoliation, little or no film or residue remains on the skin and washing the treated area is optional. The cosmetically acceptable vehicle may comprise a wide range of beneficial ingredients, cosmetic or dermatological actives and additives. The present invention also encompasses a method of exfoliating skin in need of such treatment. | 2010-05-06 |
20100111894 | METAP-2 INHIBITOR POLYMERSOMES FOR THERAPEUTIC ADMINISTRATION - Described herein are MetAP-2 inhibitors and compositions and formulations thereof, and more particularly compositions and formulations of MetAP-2 inhibitors wherein the MetAP-2 inhibitor is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. The present invention also relates to compositions and formulations comprising MetAP-2 inhibitors for oral administration or administration via routes such as topical or ocular administration. The present invention also provides methods to treat conditions associated with or related to the over-expression or over-activity of MetAP-2 by administering the compositions and formulations comprising MetAP-2 inhibitors as disclosed herein. | 2010-05-06 |
20100111895 | Human sample matching system - Methods and apparatus for a human sample (S), analyzing the sample (S) and then determining a match with a member of the opposite sex is disclosed. In one embodiment, a customer purchases an AromaMatch™ Test Kit ( | 2010-05-06 |
20100111896 | Items Containing A Human Pheromone Component - Food items, cosmetics and household items having a human pheromone component. Also disclosed are body washes, body splashes and body lotions that contain an incorporated human pheromone component or ingredient and methods for producing these products. | 2010-05-06 |
20100111897 | Methods and Compositions Useful for Diabetic Wound Healing - The invention provides compositions and methods useful for treating wounds and enhancing wound healing, particularly for diabetic wound healing. | 2010-05-06 |
20100111898 | CONJOINT THERAPY FOR TREATING FIBROTIC DISEASES - The present invention relates to improved methods of treating fibrotic or fibroproliferative disorders. Conjoint therapies are provided comprising the combination of one or more fibrocyte suppressors and one or more profibrotic factor antagonists or anti-fibrotic agents. | 2010-05-06 |
20100111899 | Materials and Methods for Immunizing Against FIV Infection - The subject invention pertains to methods and compositions for protecting feline animals from infection by FIV using immunogens derived from primate immunodeficiency viruses, including HIV and SIV. Methods for vaccinating feline animals with the subject vaccine compositions are described. Feline animals vaccinated according to the methods and compositions of the subject invention exhibit protective humoral and cellular immune responses to FIV when challenged with FIV. | 2010-05-06 |
20100111900 | HETEROCYCLIC ANTIVIRAL COMPOUNDS - Compounds having the formula I wherein R | 2010-05-06 |
20100111901 | TRIAZOLE INHIBITORS OF AROMATASE - The present invention relates to new triazole modulators of aromatase activity, pharmaceutical compositions thereof, and methods of use thereof. | 2010-05-06 |
20100111902 | COMPOSITION FOR TRANSMUCOSAL DELIVERY OF POLYPEPTIDES - The invention described herein provides an oral solid transmucosal dosage form that enhances transmucosal permeation of biologically active polypeptides across oral mucosal tissue and provides relatively rapid efficacious therapeutic onset thereof. Dosage forms prepared according to the invention can enhance transmucosal absorption of polypeptides in therapeutic serum concentrations to the recipient. The invention provides a solid dosage form for oral transmucosal absorption of a biologically active polypeptide, wherein the dosage form comprises a pharmaceutical composition comprising: a therapeutically active polypeptide; a bile salt; and an effervescent excipient component, which can comprise an effervescent couple and optionally a pH adjusting substance. The invention includes a method of administering a biologically active polypeptide, as well as a method of enhancing transmucosal absorption of a biologically active polypeptide. | 2010-05-06 |
20100111903 | COMPOSITIONS PRODUCED USING ENTERIC PATHOGENS AND METHODS OF USE - The present invention provides compositions including polypeptides having the characteristics of polypeptides expressed by a reference microbe such | 2010-05-06 |
20100111904 | MATERIAL FOR CONTROL OF SOIL-BORNE DISEASE IN PLANT UTILIZING NOVEL FILAMENTOUS FUNGI - Disclosed is a novel filamentous fungus SD-F06 strain which can infect a root of a plant and grow symbiotically with the plant and is capable of controlling a soil-borne disease. Also disclosed is a material for controlling a soil-borne disease, which comprises a fungus body or fungal culture of a filamentous fungus SD-F06 strain. Further disclosed is a method for controlling a soil-borne disease in a plant by utilizing the material. | 2010-05-06 |
20100111905 | METHODS FOR IMPROVED ENGRAFTMENT FOLLOWING STEM CELL TRANSPLANTATION - The present invention relates to methods repairing, regenerating, and reconstituting tissues by transplanting at least two stem cell populations, wherein the first and the second population of stem cells are introduced into a subject separated by a time interval of about 2 to about 24 hours. The stem cells can be derived from umbilical cord, mobilized peripheral blood, or bone marrow. The cells of at least the second population may be enriched for adult stem and progenitor cells. The methods of the invention are useful in accelerating hematopoeitic recovery in subjects following myeloablation or chemotherapy. | 2010-05-06 |
20100111906 | VOLUME MAINTAINING OSTEOINDUCTIVE/OSTEOCONDUCTIVE COMPOSITIONS - An osteoinductive/osteoconductive composition prepared from a quantity, of demineralized fibrous bone elements possessing an average surface area to volume ratio of about 100:1 to about 20:1, a quantity of mostly shaped regular non-fibrous bone elements possessing an average surface area to volume ratio of about 10:1 or less and a sufficient quantity of biocompatible fluid carrier sufficient to provide the composition as a deformable mass is provided herein. Also provided is a method of using the composition to repair a bone defect site. | 2010-05-06 |
20100111907 | Methods and compositions for gene inactivation - Disclosed herein are methods and compositions for inactivating CCR-5 genes, using zinc finger nucleases (ZFNs) comprising a zinc finger protein and a cleavage domain or cleavage half-domain. Polynucleotides encoding ZFNs, vectors comprising polynucleotides encoding ZFNs, such as adenovirus (Ad) vectors, and cells comprising polynucleotides encoding ZFNs and/or cells comprising ZFNs are also provided. | 2010-05-06 |
20100111908 | Induction of Renal Cells for Treatment of Kidney Disease - Methods and systems for the generation of induced renal cells are provided. For example, methods for inducing renal cells from lineage undifferentiated hematopoietic stem and/or progenitor cell incubated with growth factors are described. Furthermore, the invention provides methods for using induced renal cells for treating a renal disease and/or injury. | 2010-05-06 |
20100111909 | Dedifferentiation of Adult Mammalian Cardiomyocytes into Cardiac Stem Cells - Dedifferentiation is a mechanism whereby specialized cells regain properties of their ancestors, including, in the extreme, stemness. We found that highly-purified cardiomyocytes isolated from adult mammalian hearts dedifferentiated rapidly when cultured in mitogen-rich medium. Such myocytes reentered the cell cycle and proliferated, expressing stem cell surface markers such as c-kit and early cardiac transcription factors including GATA and NKx2.5. These myocyte-derived cells (MDC) were capable of re-differentiating into myocytes and endothelial cells. Contrary to prevailing dogma, cardiomyocyte dedifferentiation yields proliferative cells expressing stem cell markers and capable of multilineage differentiation. Cardiomyocyte dedifferentiation is a potential source of endogenous stem cells in the adult heart. | 2010-05-06 |
20100111910 | Treatment of excessive neovascularization - The present invention relates to methods of treating or preventing angiogenesis-related diseases by the administration of stem cells and/or progeny cells thereof. | 2010-05-06 |
20100111911 | MITOCHONDRIAL NUCLEIC ACID DELIVERY SYSTEMS - Nucleic acid mitochondrial delivery systems are provided. These systems are important for delivery of genetic information to a mitochondrion and for treatment of mitochondrial related diseases. | 2010-05-06 |
20100111912 | COMPOSITIONS AND METHODS FOR TARGETED ABLATION OF MUTATIONAL ESCAPE OF TARGETED THERAPIES FOR CANCER - Provided herein are compositions and methods for targeted ablation of mutational escape in the face of cancer therapeutic agents. Compositions comprising the yeast-based vehicles are used in combination with other cancer therapeutic agents. | 2010-05-06 |
20100111913 | METHOD OF ENHANCING MIGRATION OF NEURAL PRECURSOR CELLS - There is provided methods relating to enhancing migration of a neural precursor cell by augmenting levels of TMEM18 protein in the neural precursor cell. Such methods may be used in the treatment of disorders, including treatment of a glioma or a neurodegenerative disorder. | 2010-05-06 |
20100111914 | STEM CELLS FROM URINE AND METHODS FOR USING THE SAME - Provided herein are stem cells and methods for producing a culture of stem cells from urine. The stem cells may be differentiated into an osteogenic, chondrogenic, adipogenic, endothelial, neurogenic or myogenic lineage. Methods of use of the cells are provided, including methods of treating a subject in need of a cell based therapy. | 2010-05-06 |
20100111915 | PROBIOTICS FOR REDUCTION OF RISK OF OBESITY - The use of probiotic bacteria capable of promoting the development of an early bifidogenic intestinal microbiota in the manufacture of a medicament or therapeutic nutritional composition for reducing the risk of development of overweight or obesity of an infant later in life. | 2010-05-06 |
20100111916 | Materials and Method of Modulating the Immune Response - Methods and materials to modulate the immune response to treat or prevent a disease or to prevent transplant rejection, including methods of making T helper-antigen presenting cells and/or T regulatory-antigen specific cells and methods of using these cells. The invention also relates to methods of making exosome-absorbed dendritic cells and the uses of these cells to modulate the immune response to treat or prevent a disease or to prevent transplant rejection. | 2010-05-06 |